pdufa.bio

Andembry (garadacimab-gxii)

Page updated ·next FDA decision on the calendar ·Data as of Oct 11, 2026 9:31 PM ET

Andembry (garadacimab-gxii) The FDA approved it on Jun 16, 2025. 1 FDA decision on record below. Every date links its source.

HOTH catalyst hub

All upcoming FDA decision dates on the 2026 PDUFA calendar

About this program

We track 1 catalyst event for this program: 0 upcoming and 1 in the record. A PDUFA date is the FDA's target date to complete review of a marketing application; a readout is the sponsor's expected date for clinical trial results. What a PDUFA date is · why we do not compare trial results across drugs.

Catalyst history

FDA decision · Jun 16, 2025 ✓ ApprovedHOTH

Questions

When is Andembry (garadacimab-gxii)'s next FDA decision or readout?

No upcoming catalyst is on our calendar for Andembry (garadacimab-gxii); 1 FDA decision is on record below.

What happened at Andembry (garadacimab-gxii)'s most recent FDA decision?

On Jun 16, 2025 the FDA approved the application. The decision page carries the source document and the measured share-price reaction.

Has Andembry (garadacimab-gxii) been approved by the FDA?

Yes. The FDA approved an application for Andembry (garadacimab-gxii) on Jun 16, 2025; the decision page linked above carries the source.

Where does this data come from?

FDA announcements, sponsor press releases and SEC filings; every date on this page links its source.